12:16 PM EST - MYND Life Sciences : Announced positive preclinical data in measuring dosing accuracy in psilocybins and psilocybin analogs. Today, Mynd announces substantial advances in creating a molecular test for calibrating and measuring cellular responses to microdosing with psilocybin. MYND Life Sciences
shares C.MYND are trading up $0.02 at $0.07.
